PEOPLE - Luminex makes appointments:
This article was originally published in Clinica
Three newly-created management positions have been established by biological testing technologies firm Luminex (Austin, Texas). Dr James Jacobson, chairman of the firm's scientific advisory board, becomes vice-president and chief scientific officer; Dr John Carrano has been promoted to vice-president of R&D and a member of the advisory board; and Oliver Meek has been named as vice-president of quality assurance and regulatory affairs.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.